Absci

What Absci does

Absci is a publicly traded (NASDAQ: ABSI) generative AI drug creation company founded in 2011 and headquartered in Vancouver, Washington, with research facilities in New York, Belgrade, and Zug (Switzerland), and clinical operations in Sydney, Australia. The company's core offering is an Integrated Drug Creation Platform that combines proprietary synthetic biology (SoluPro), high-throughput wet-lab screening (ACE Assay, >4,000x traditional throughput), and generative AI models (Origin-1, AbsciGen comprising AbsciDiff and IgDesign2, and AbsciBind for scoring) in a 6-week Lab-in-the-Loop cycle. This platform is designed to enable de novo antibody design against undruggable and zero-prior epitopes, multiparametric lead optimization, and AI-enabled target discovery via Reverse Immunology, generating approximately 2.97 billion proprietary protein-protein interaction data points weekly to feed its models.

Absci operates a dual business model combining platform partnership revenue with internal pipeline development. Partnership revenue is generated through multi-year collaboration agreements with large pharmaceutical companies that include upfront payments, research funding, milestone payments, and royalties; notable deals include Merck ($610M potential value), AstraZeneca ($247M), and Almirall. The internal pipeline includes ABS-201, an AI-designed anti-prolactin receptor antibody in Phase 1/2a for androgenetic alopecia with Phase 2 in endometriosis planned for Q4 2026, and ABS-202 in preclinical development for an inflammation and immunology indication. Strategic compute partnerships with AMD, Oracle Cloud Infrastructure, and NVIDIA provide the underlying AI infrastructure. As of year-end 2025, Absci had ~$144.3M in cash supporting runway into H1 2028, FY2025 revenue of ~$2.8M, R&D expense of $81.4M, and a net loss of $115.2M, reflecting its pre-commercial clinical-stage status.

Name

Absci

Legal name

Absci Corporation

Website

https://absci.com

Company type

Public

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

Absci is a publicly traded generative AI drug creation company that combines proprietary synthetic biology and deep learning to design and validate novel biologic drug candidates, serving large pharmaceutical partners and advancing its own internal pipeline of AI-designed antibody therapeutics.

Ownership category

akta.pro rank

Product category

AI Drug Discovery Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Generative AI drug discovery
• Biologics design platform
• Antibody engineering
• AI drug creation
• De novo antibody design

Headquarters

HQ city

Vancouver

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Partnership/Collaboration Revenue: Absci generates revenue through strategic partnerships with pharmaceutical companies including upfront payments, research funding, milestone payments, and potential royalties. Examples include Merck ($610M biobucks deal) and AstraZeneca ($247M AI-enabled oncology pact).
2. Equity Financing: The company raised $100M in June 2026 underwritten offering with Eli Lilly investing $40M. Also maintains ATM (at-the-market) share issuance programs.
3. Internal Pipeline Development: Developing proprietary therapeutic candidates (ABS-201, ABS-202, ABS-101) with plans to commercialize independently or partner later-stage assets.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Absci operates an Integrated Drug Creation Platform that combines generative AI models with proprietary high-throughput wet lab validation (SoluPro synthetic biology and ACE Assay) to enable de novo antibody design, multi-parametric lead optimization, and novel target discovery via reverse immunology. The platform serves pharmaceutical and biotech partners through drug creation collaborations structured with upfront payments, R&D funding, milestone payments, and royalties, while Absci simultaneously develops an internal pipeline of AI-designed therapeutics including ABS-201 (anti-PRLR antibody for androgenetic alopecia and endometriosis) and ABS-202.

Product overview

Absci is a generative AI drug creation company operating a unified Integrated Drug Creation Platform that combines high-throughput wet lab data generation (SoluPro, ACE Assay) with generative AI models (AbsciGen, AbsciBind) and multiparametric AI lead optimization. The platform enables de novo antibody design and novel target discovery via reverse immunology. Key pipeline products include ABS-201 (anti-PRLR antibody in Phase 1/2a for androgenetic alopecia and Phase 2 planning for endometriosis), ABS-202 (preclinical anti-PRLR for inflammation/I\&I), and internal/preclinical programs. The Origin-1 platform extends de novo capabilities to zero-prior epitopes. Absci partners with pharma companies (AstraZeneca, Merck, Almirall) and technology providers (Oracle, AMD, NVIDIA) to power its platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Integrated Drug Creation Platform Absci's core AI-powered drug creation platform that integrates wet lab and AI in iterative cycles, enabling de novo design of biologics and multiparametric lead optimization. Processes high-throughput protein-protein interaction data (2.97+ billion data points weekly) to train generative AI models, create antibody designs in silico, and validate candidates in wet lab within six weeks. Sold to pharmaceutical partners via strategic collaborations.
• Origin-1 A generative AI platform for de novo design of full-length monoclonal antibodies against 'zero-prior' epitopes (target sites with no reported complex structures). Delivers specific, developable binders in fewer than 100 designs per target with atomic accuracy validated by cryo-EM. Uses AbsciGen (AbsciDiff + IgDesign2) as the generative engine and AbsciBind as the scoring/filtering engine.
• ABS-201 (Androgenetic Alopecia) An AI-designed anti-prolactin receptor (PRLR) monoclonal antibody for the treatment of androgenetic alopecia (AGA). Demonstrated superior hair regrowth versus minoxidil in preclinical studies, with a Phase 1/2a HEADLINE trial initiated in December 2025. Estimated half-life of at least 65 days supports 2-3 doses over six months.
• ABS-201 (Endometriosis) Indication expansion of ABS-201 anti-PRLR antibody for endometriosis as a non-sex-steroid hormonal therapeutic. Preclinical data demonstrated significant reductions in both spontaneous and evoked pain behaviors and suppression of inflammatory cytokines. Phase 2 trial targeted to initiate in Q4 2026.
• ABS-202 A second anti-PRLR antibody in preclinical development targeting an inflammation and immunology indication, announced in 2026 as part of Absci's expanded prolactin program portfolio.
• Reverse Immunology (AI Target Discovery) AI-enabled approach for novel therapeutic target discovery that identifies antibodies from patient samples of super immune responders, reconstructs fully human antibody sequences in silico, and pairs them with target antigens for AI optimization and IND-enabling studies.

Quantifiable outcome

• AI-designed antibodies validated from concept to clinical trial pipeline in ~24 months
• +7 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature9 records

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

• Oracle Cloud InfrastructurecoreTechnology or Integration · 12 September 2025Collaboration to accelerate generative AI-driven drug discovery using OCI AI infrastructure and AMD GPUs. Enables Absci to consolidate infrastructure, reduce inter-GPU latency to 2.5 microseconds, and scale large-scale molecular-dynamics simulations.
• AlmirallmajorStrategic or Co-development Partner · 2 September 2025Expanded collaboration to accelerate AI-powered drug discovery for skin diseases. Almirall's Karl Ziegelbauer stated: 'Almirall chose Absci because their de novo platform brings truly novel innovation to the industry's most challenging targets with high unmet medical need.'
• Memorial Sloan Kettering Cancer CentermajorStrategic or Co-development Partner · 12 August 2024AI antibody generator collaboration for cancer research. Absci inks cancer collaboration with Memorial Sloan Kettering for AI-designed antibody therapeutics in oncology.
• AstraZenecacoreStrategic or Co-development Partner · 4 December 2023$247M AI-enabled oncology antibody design pact. Absci applies its de novo AI antibody creation platform to design potential new antibody therapy in oncology. AstraZeneca's Puja Spara stated: 'This collaboration is an exciting opportunity to utilize Absci's de novo AI antibody creation platform to design a potential new antibody therapy in oncology.'
• Merck (MSD)coreStrategic or Co-development Partner · 7 January 2022$610M biobucks drug discovery partnership (potential milestones and royalties). Merck Global Health Innovation Fund's Prem Tumkosit noted Absci falls into 'Next Horizon' technologies with potential to disrupt biopharma industry.
• AMDcoreTechnology or IntegrationAMD invested in Absci and partnered to scale AI drug discovery using AMD Instinct MI355X GPUs. Mark Papermaster (CTO at AMD) stated: 'We are proud to partner with Absci, a company at the forefront of AI-driven drug discovery, to help further accelerate breakthroughs in therapeutics.'
• NVIDIAmajorTechnology or IntegrationNVIDIA powers Absci's in silico technologies. Kimberly Powell (VP Healthcare at NVIDIA) stated: 'Absci's powerful data generation and AI protein engineering platform is already helping the drug discovery industry, and NVIDIA is excited to help power and scale Absci's in silico technologies to achieve the best positive impact.'
• OwkinmajorStrategic or Co-development PartnerCo-development partnership for immuno-oncology candidates. Owkin's Thomas Clozel (CEO) stated: 'This partnership with Absci represents a significant step forward in our journey to bring transformative therapies to patients. By bringing together Owkin's AI agents that can identify and experimentally validate novel therapeutic targets with Absci's pioneering capabilities in developing biologic drug candidates, we aim to accelerate the delivery of next-generation treatments.'
• PrecisionLifemajorStrategic or Co-development PartnerR&D partnership combining leading generative AI approaches with PrecisionLife's unique disease biology insights. Steve Gardner (CEO of PrecisionLife) stated: 'Our partnership demonstrates the transformational innovation potential of coupling leading generative AI approaches with PrecisionLife's unique disease biology insights.'
• CaltechmajorStrategic or Co-development PartnerHIV vaccine research collaboration funded by Bill & Melinda Gates Foundation. Absci designs antibody or antibody-like protein to bind to conserved HIV target exposed during cell infection process, in partnership with Caltech researchers.
• InvetxminorStrategic or Co-development PartnerPartnership for innovative specialty therapeutics for companion animals. Juergen Horn (President of Invetx) stated: 'We selected Absci for this collaboration because of their leading platform for generative AI design of human antibodies.'
• Oxford UniversityminorStrategic or Co-development PartnerAcademic partnership for AI-driven biological research and antibody development

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Generate Biomedicines: Generate Biomedicines is a generative AI biology company designing de novo protein therapeutics, directly comparable to Absci's Origin-1 and Integrated Drug Creation Platform. Both compete for large-pharma partnership deals centered on AI-designed antibodies and novel biologics.
• AbCellera Biologics: AbCellera is a public antibody discovery platform that combines high-throughput wet lab screening with machine learning to identify lead candidates for pharma partners. It competes head-to-head with Absci's SoluPro/ACE Assay stack and is similarly partnered with major pharmaceutical companies.
• BigHat Biosciences: BigHat Biosciences uses AI/ML-guided antibody design with an integrated wet lab loop, mirroring Absci's lab-in-the-loop approach. Both target the same customer base (pharma seeking AI-designed antibody leads) and compete on cycle time, developability, and success rates.
• Insilico Medicine: Insilico Medicine operates an AI-driven drug discovery platform that combines generative chemistry, target identification, and clinical development. While broader in modality than Absci, it is a directly comparable AI biotech pursuing pharma partnerships and an internal pipeline.
• Recursion Pharmaceuticals: Recursion is a publicly traded AI-driven drug discovery company combining high-throughput biology with machine learning to identify novel therapeutics. Like Absci, it pursues both a partnership model and an internal pipeline, and competes for similar pharma and investor mindshare.
• Schrödinger: Schrödinger provides computational chemistry and physics-based software for drug discovery, serving many of the same pharmaceutical customers as Absci. It is comparable as a public, platform-oriented AI-for-drug-discovery company monetized through software and partnerships.
• Adimab: Adimab operates a proprietary antibody discovery and optimization platform serving pharma and biotech partners. It is directly comparable to Absci's antibody discovery and lead-optimization offering and competes for similar partnership economics.

Broad incumbents

• Isomorphic Labs: Isomorphic Labs is Alphabet's commercial AI drug discovery business, applying DeepMind's protein-structure and generative modeling to pharma partnerships. As a deep-pocketed incumbent with overlapping capability to Absci's Origin-1, it is the most consequential broad competitor in the AI biologics design space.

Emerging players

• Cradle Bio: Cradle is an AI protein engineering platform that uses generative models to help partners design improved proteins, including antibodies and enzymes. It overlaps with Absci's generative biology capabilities and targets a similar partner base, with a narrower focus on protein design.
• EvolutionaryScale: EvolutionaryScale is an AI protein design company developing frontier generative models for protein engineering. While earlier-stage and more research-oriented, it competes for the same AI-for-proteins narrative and could attract comparable pharma collaborations in the longer term.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/abscibio
• YouTubeyoutube.com/c/absci
• LinkedInlinkedin.com/company/absci
• Facebookfacebook.com/abscibio

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds14 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Absci